论文部分内容阅读
目的研讨心力衰竭患者实施阿托伐他汀治疗的临床有效性与安全性。方法选择我院2015年1月-2016年1月诊疗的80例心力衰竭患者进行试验分析,并按随机自愿原则归组(40例/组),Ⅰ组接受常规抗心衰治疗,Ⅱ组在上述条件下接受阿托伐他汀口服,1个疗程后,评估两组的心功能、血清IL-6及hs-CRP等指标水平。结果Ⅱ组接受治疗后6个月的LVEF、LVSD及LVIDd值相比治疗前均显著改善(P<0.05),但与Ⅰ组相比差异不显著(P>0.05);接受治疗后1年,Ⅱ组上述心功能指标相比Ⅰ组均显著改善(P<0.05)。Ⅱ组接受治疗后6个月、1年的血清IL-6与hs-CRP值与同组治疗前、Ⅰ组同时段数据相比,差异均显著(P<0.05)。两组试验期间均未产生严重的药物副反应。结论在常规抗心衰的基础上,对心力衰竭患者施加阿托伐他汀口服,方案药效显著、安全性高,且对清除心肌细胞炎症因子具有一定作用,值得加强推广。
Objective To investigate the clinical efficacy and safety of atorvastatin in patients with heart failure. Methods Eighty patients with heart failure diagnosed and treated in our hospital from January 2015 to January 2016 were selected and randomly divided into group (40 cases / group), group Ⅰ received routine anti-heart failure treatment, group Ⅱ Under the above conditions, atorvastatin was taken orally and after 1 course of treatment, the cardiac function, serum IL-6 and hs-CRP levels were evaluated. Results The levels of LVEF, LVSD and LVIDd in group Ⅱ were significantly improved at 6 months after treatment (P <0.05), but not significantly different from those in group Ⅰ (P> 0.05). One year after treatment, The cardiac function indexes of group Ⅱ were significantly improved compared with group Ⅰ (P <0.05). The levels of IL-6 and hs-CRP in group Ⅱ at 6 months and 1 year after treatment were significantly higher than those in group Ⅰ before and after treatment (P <0.05). During the two groups did not produce serious side effects of the drug. Conclusions On the basis of routine anti-heart failure, atorvastatin orally administered to patients with heart failure has significant efficacy and safety, and plays a role in eliminating cardiomyocyte inflammatory cytokines. It is worth to be promoted.